Neurological Biomarker Market Share & Growth | Forecast 2030
Neurological Biomarker Market Share & Growth | Forecast 2030
Segments - Neurological Biomarker Market by Types (Proteomic, Imaging, Genomic, Metabolomics, and Others), Applications (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), End-users (Independent Clinical Diagnostic Centers, Hospital Laboratories, Research Organizations, and Others) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
Upcoming
| Report ID :HC-1432
| 4.9 Rating
| 76 Reviews
| 184 Pages
| Format :
Report Description
The global neurological biomarkers market size is estimated to record a considerable CAGR during the forecast period, 2021–2028. The rising market is owing to the increasing in nervous disorder as well as the growing awareness on the neurological disease detection and treatment.
Neurological biomarkers refer to the molecules in the blood or cerebral spinal fluid (CSF) that assist the prognosis of mind issues and display ailment progression. The fundamental reasserts biomarkers are genetic metabolite levels, mutations, mind imaging and adjustments in protein expression. As they discover organic responses to experimental capsules and resource in coming across new goals for healing intervention, neurological biomarkers are broadly utilized in scientific exercise throughout drug development. At present, researchers’ degree biomarker concentrations to offer non-invasive testing, in advance prognosis, and personalized treatments.
According to World Health Organization (WHO), globally more than 300 million people were suffering from clinical depression in 2018. As per the estimation of École des Neurosciences de Paris Île-de-France, over 6 million people are dying caused by stroke every year and the mortality rate is close to 80% in low and middle income countries. Over 600 neurological diseases have been discovered that can affect the nerves, brain, and spine in human’s body, which lead to the leading causes of several neurological disorders. Some of the examples of neuro-disorders are such as Alzheimer’s disease, brain tumors, cerebral stroke, epilepsy and Parkinson’s disease.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing cases of neurological disorders such as stroke, motor neuron disease, Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease especially in developed countries are fueling the biomarkers’ market growth.
- Largely adoption of minimally invasive procedures and personalized medicines are driving the market growth.
- Rising number of clinical trials and advent of digital biomarkers are anticipated to propel the market expansion during the forecast period.
- Less awareness of neurological diseases and lack of treatment facilities in low income countries are the factors hampering the market growth.
- High cost involved in neuro- research & development affects the market share in low & middle income level countries. This is expected to hamper the market growth in the coming years.
Scope of the Report
The report on the global neurological biomarker market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Neurological Biomarker Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Types (Proteomic, Imaging, Genomic, Metabolomics, and Others), Applications (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), End-users (Independent Clinical Diagnostic Centers, Hospital Laboratories, Research Organizations, and Others) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Abbott; QIAGEN; Myriad RBM; Thermo Fisher Scientific Inc.; Athena Diagnostics; Bio-Rad Laboratories, Inc.; AbaStar MDx, Inc.; Acumen Pharmaceuticals; BANYAN BIOMARKERS, Inc.; and Alseres Pharmaceuticals, Inc. |
Market Segment Insights
Genomic segment is expected to dominate the market
Based on types, the neurological biomarkers market is categorized as proteomic, imaging, genomic, metabolomics, and others. The genomic segment is expected to dominate the market during the forecast period owing to increasing adoption of advanced technology for genomic research and increasing awareness of the biomarker type. Moreover, rising shift of diagnostic paradigm towards the advancement of gene evaluation and genetic counselling pave a key aspect for the segment growth. Genomic biomarkers are directing towards neurological exercise regarding personalized technique primarily based on patient’s character genetic specifications and predispositions. On the other hand, the imaging segment is projected to hold a large market share during the forecast period due to the aid of using considerable R&D in neuroscience and technological improvements, which have enabled visualization of abnormalities in the body.
Alzheimer’s disease segment is projected to expand at a considerable market
Based on the applications, the market is divided into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, autism spectrum disorders, and others. The Alzheimer’s disease segment is projected to expand at a considerable market share in the coming years as wide prevalence of the disease in many developed countries and wide adoption of neurological biomarkers for the treatment of the disease. Amyloid-β, general tau, and phosphorylated tau are the important cerebrospinal fluid biomarkers that are widely adopted for reflecting the pathophysiology of this disease. Identification of those biomarkers with in the initial levels of the disorder can assist in timely treatment.
Meanwhile, the Parkinson’s disease segment is anticipated to exhibit a healthy CAGR during the projected period due to the emerging disruptive studies and trials ongoing for advanced diagnostics of Parkinson’s disorder. Earlier, protein biomarkers, amino acids, and dopamine metabolites had been the high analytical gear for diagnosing Parkinson’s disorder. Moreover, numerous novel applicants are volunteering for the disease research purpose by diagnostic biomarkers, which is expected to boost the segment growth.
Hospital laboratories segment is anticipated to gain a large market share
On the basis of end-users, the neurological biomarkers market is segmented into independent clinical diagnostic centers, hospital laboratories, research organizations, and others. The hospital laboratories segment is anticipated to gain a substantial market share during the forecast period. The segment growth can be attributed to growing affected person influx for most cancers prognosis in hospitals, developing patron awareness, and growing investments in healthcare infrastructure in growing and underdeveloped countries. On the other hand, the research organizations segment is expected to grow at a considerable rate during the forecast period attributing to the huge investments for neuroscience research worldwide. For example, the NINDS Human Biomarkers Biospecimen and Data Repository is dedicated to advanced research and determination of neurological biomarkers.
North America is estimated to dominate the market
In terms of regions, the global neurological biomarkers market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is projected to dominate the market during the forecast period due to evident business trend of neurological diagnostics in the region especially in the U.S. Some of the other factors fueling the market growth include proactive government initiatives, rising expenditure in healthcare infrastructure, and local presence of major manufacturers in the region.
The market of Asia Pacific, on the other hand, is expected to expand rapidly during the forecast period. The regional growth rate is anticipated to be influenced by overall economic development, improvements in healthcare infrastructure, increased personal disposable income, and rising consumer awareness. Emerging economies such as China, India, and South Korea are encouraging a wide scale development programs and research for biomarkers, which are likely to boost the regional market expansion in the coming years.
Segments
Segments Covered in the Report
The global neurological biomarker market has been segmented on the basis of
Types
- Proteomic
- Imaging
- Genomic
- Metabolomics
- Others
Applications
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Autism Spectrum Disorders
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Abbott
- QIAGEN
- Myriad RBM
- Thermo Fisher Scientific Inc.
- Athena Diagnostics
- Bio-Rad Laboratories, Inc.
- AbaStar MDx, Inc.
- Acumen Pharmaceuticals
- Banyan Biomarkers, Inc.
- Alseres Pharmaceuticals, Inc.
Competitive Landscape
Some of the major players competing in the market are Abbott; QIAGEN; Myriad RBM; Thermo Fisher Scientific Inc.; Athena Diagnostics; Bio-Rad Laboratories, Inc.; AbaStar MDx, Inc.; Acumen Pharmaceuticals; BANYAN BIOMARKERS, Inc.; and Alseres Pharmaceuticals, Inc.
To expand their market reach, major market players are indulged in innovation and development of new products. Market players are stepping into merger & acquisitions, licensing partnerships, and co-development to stay ahead in the market competition. For example, Abbott acquired Alere Inc. in September 2017, which was expected to help the company to expand the point of care division into business portfolio.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Neurological Biomarker Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Neurological Biomarker Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Neurological Biomarker Market - Supply Chain
4.5. Global Neurological Biomarker Market Forecast
4.5.1. Neurological Biomarker Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Neurological Biomarker Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Neurological Biomarker Market Absolute $ Opportunity
5. Global Neurological Biomarker Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Neurological Biomarker Market Size and Volume Forecast by Types
5.3.1. Proteomic
5.3.2. Imaging
5.3.3. Genomic
5.3.4. Metabolomics
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Neurological Biomarker Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Neurological Biomarker Market Size and Volume Forecast by Applications
6.3.1. Alzheimer’s Disease
6.3.2. Parkinson’s Disease
6.3.3. Multiple Sclerosis
6.3.4. Autism Spectrum Disorders
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Neurological Biomarker Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Neurological Biomarker Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Neurological Biomarker Demand Share Forecast, 2019-2026
8. North America Neurological Biomarker Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Neurological Biomarker Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Neurological Biomarker Market Size and Volume Forecast by Types
8.4.1. Proteomic
8.4.2. Imaging
8.4.3. Genomic
8.4.4. Metabolomics
8.4.5. Others
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Neurological Biomarker Market Size and Volume Forecast by Applications
8.7.1. Alzheimer’s Disease
8.7.2. Parkinson’s Disease
8.7.3. Multiple Sclerosis
8.7.4. Autism Spectrum Disorders
8.7.5. Others
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Neurological Biomarker Demand Share Forecast, 2019-2026
9. Latin America Neurological Biomarker Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Neurological Biomarker Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Neurological Biomarker Market Size and Volume Forecast by Types
9.4.1. Proteomic
9.4.2. Imaging
9.4.3. Genomic
9.4.4. Metabolomics
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Neurological Biomarker Market Size and Volume Forecast by Applications
9.7.1. Alzheimer’s Disease
9.7.2. Parkinson’s Disease
9.7.3. Multiple Sclerosis
9.7.4. Autism Spectrum Disorders
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Neurological Biomarker Demand Share Forecast, 2019-2026
10. Europe Neurological Biomarker Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Neurological Biomarker Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Neurological Biomarker Market Size and Volume Forecast by Types
10.4.1. Proteomic
10.4.2. Imaging
10.4.3. Genomic
10.4.4. Metabolomics
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Neurological Biomarker Market Size and Volume Forecast by Applications
10.7.1. Alzheimer’s Disease
10.7.2. Parkinson’s Disease
10.7.3. Multiple Sclerosis
10.7.4. Autism Spectrum Disorders
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Neurological Biomarker Demand Share Forecast, 2019-2026
11. Asia Pacific Neurological Biomarker Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Neurological Biomarker Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Neurological Biomarker Market Size and Volume Forecast by Types
11.4.1. Proteomic
11.4.2. Imaging
11.4.3. Genomic
11.4.4. Metabolomics
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Neurological Biomarker Market Size and Volume Forecast by Applications
11.7.1. Alzheimer’s Disease
11.7.2. Parkinson’s Disease
11.7.3. Multiple Sclerosis
11.7.4. Autism Spectrum Disorders
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Neurological Biomarker Demand Share Forecast, 2019-2026
12. Middle East & Africa Neurological Biomarker Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Neurological Biomarker Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Neurological Biomarker Market Size and Volume Forecast by Types
12.4.1. Proteomic
12.4.2. Imaging
12.4.3. Genomic
12.4.4. Metabolomics
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Neurological Biomarker Market Size and Volume Forecast by Applications
12.7.1. Alzheimer’s Disease
12.7.2. Parkinson’s Disease
12.7.3. Multiple Sclerosis
12.7.4. Autism Spectrum Disorders
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Neurological Biomarker Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Neurological Biomarker Market: Market Share Analysis
13.2. Neurological Biomarker Distributors and Customers
13.3. Neurological Biomarker Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
Methodology
Related Reports
Some other reports from this category!
Our Clients
